NASDAQ · Biotechnology
ADPT (ADPT) Stock
$24.93
+5.64%
NASDAQ: ADPT
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Motley Fool · Jul 12, 2026
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
GlobeNewswire · Jul 9, 2026
Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing
MT Newswires · Jul 8, 2026
Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing
MT Newswires · Jul 7, 2026
Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial
Exec Edge · Jun 30, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.84%
Institutions Held96.60%
Institutions Float Held98.41%
Peer Comparison
About ADPT
ADPT stock trades at $24.93 with a market capitalization of $3.99B. The stock is valued at a price-to-earnings (P/E) ratio of -69.84, price-to-book of 13.03, price-to-sales of 9.57. Over the past 52 weeks the stock has ranged between $9.96 and $24.93, and currently trades at its 52-week high.
On profitability, ADPT generates a return on equity (ROE) of -23.95%, return on capital employed of -25.33%, an operating margin of -15.82%, a net profit margin of -16.82%.